
Mixed top-line results for Viking’s oral obesity drug
Viking Therapeutics has released positive top-line results from its Phase II clinical trial of the oral tablet formulation of VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is being developed in both oral and subcutaneous formulations for… Read More















